Hepatology News Tonight - Managing Complications of Cirrhosis
This activity was recorded at a satellite symposium event concurrent with the 2019 SHM Annual Conference.
Target Audience
This activity has been designed to meet the educational needs of physicians, advanced practice providers and allied health professionals who provide care for hospitalized patients with liver disease.
Learning Objectives
After completing this enduring activity, participants should be better able to:
- Understand the complications and the consequences of cirrhosis
- Describe the economic, patient, and caregiver burdens associated with cirrhosis
- Demonstrate the ability to properly treat the complications of cirrhosis and prevent recurrence
Accredited by:
Rehoboth McKinley Christian Health Care Services
Provided by:
Chronic Liver Disease Foundation
Supported by educational grants from Mallinckrodt and Salix Pharmaceuticals.
Accreditation
Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the New Mexico Medical Society (NMMS) through the joint providership of Rehoboth McKinley Christian Health Care Services (RMCHCS), the Chronic Liver Disease Foundation (CLDF), and the Texas Gulf Coast Gastroenterological Society (TGCGS). RMCHCS is accredited by the NMMS to provide continuing medical education for physicians.
RMCHCS designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Robert S. Brown, Jr., MD, MPH (Chair)
Gladys and Roland Harriman Professor of Medicine
Vice Chair for Mentorship and Academic Development
Clinical Chief, Division of Gastroenterology and Hepatology
Weill Cornell Medicine
New York, New York
Dr. Brown reports the following relationships related to this activity:
Honoraria recipient: AbbVie, Dova, Gilead, Intercept, Merck, and Shionogi, Inc.
Consultant/Research Support: AbbVie, Dova, Gilead, Intercept, Merck, and Shionogi, Inc.
Kimberly Brown, MD, FAST, FAASLD, AGAF
Professor of Medicine at Wayne State University
Chief, Gastroenterology and Hepatology
Associate Medical Director, Henry Ford Hospital Transplant Institute
Henry Ford Hospital
Detroit, Michigan
Dr. Brown reports the following relationships related to this activity:
Honoraria recipient: Gilead, Pfizer, and Merck.
Consultant/Research Support: Allergan, Conatus, Gilead, and Novartis.
Steven Flamm, MD, FAASLD, FACG
Chief of Hepatology and Liver Transplantation Program
Professor of Medicine and Surgery
Northwestern Feinberg School of Medicine
Chicago, Illinois
Dr. Flamm reports the following relationships related to this activity:
Honoraria recipient: Dova and Salix Pharmaceuticals.
Consultant/Research Support: Dova and Salix Pharmaceuticals.
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the New Mexico Medical Society (NMMS) through the joint providership of Rehoboth McKinley Christian Health Care Services (RMCHCS), the Chronic Liver Disease Foundation (CLDF) and the Texas Gulf Coast Gastroenterological Society (TGCGS). RMCHCS is accredited by the NMMS to provide continuing medical education for physicians.
RMCHCS designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Non-physician